Data Sheet (Cat.No.T8431)

TargetMol

JCN037

Chemical Properties



CAS No. : 2305154-31-6

Formula: C16H11BrFN3O2

Molecular Weight: 376.18

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvIII with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).
Targets(IC50)	EGFR
In vivo	Relative to the conventional EGFR TKIs erlotinib and lapatinib, JCN037 displayed potent activity against EGFR amplified/mutant patient-derived cell cultures, significant BBB penetration (2:1 brain-to-plasma ratio), and superior efficacy in an EGFR-driven orthotopic glioblastoma xenograft model.

Solubility Information

Solubility	DMSO: 10 mg/mL (26.58 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 1 mg/mL (2.66 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6583 mL	13.2915 mL	26.583 mL
5 mM	0.5317 mL	2.6583 mL	5.3166 mL
10 mM	0.2658 mL	1.3292 mL	2.6583 mL
50 mM	0.0532 mL	0.2658 mL	0.5317 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jonathan E. Tsang, et al. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Med. Chem. Lett. 2020. May 1.